Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells

Journal of Medical Microbiology

Volumn 61, Issue 3, 2012, Pages 375-383

  Liao, Yalin ^a,b   El Fakkarany, Esmail ^c   Lönnerdal, Bo ^a   Redwan, Elrashdy M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c City of Scientific Research and Technological Applications   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LACTOFERRIN; NATIVE CAMEL LACTOFERRIN; RECOMBINANT CAMEL LACTOFERRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; HEPATITIS C; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CAMELS; CELL LINE; CYTOPLASM; HEPACIVIRUS; HEPATOCYTES; HUMANS; LACTOFERRIN; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS INTERNALIZATION;

EID: 84857075449     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.033894-0     Document Type: Article

References (37)

1. Abe, K., Nozaki, A., Tamura, K., Ikeda, M., Naka, K., Dansako, H., Hoshino, H. O., Tanaka, K. & Kato, N. (2007). Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol 51, 117-125.
2. Al-Majali, A. M., Ismail, Z. B., Al-Hami, Y. & Nour, A. Y. (2007). Lactoferrin concentration in milk from camels (Camelus dromedarius) with and without subclinical mastitis. Intern J Appl Res Vet Med 5, 120-124.
3. Alter, M. J. (2007). Epidemiology of hepatitis C virus infection. World J Gastroenterol 13, 2436-2441.
4. Azzam, H. S., Goertz, C., Fritts, M. & Jonas, W. B. (2007). Natural products and chronic hepatitis C virus. Liver Int 27, 17-25.
5. Blight, K. J., McKeating, J. A. & Rice, C. M. (2002). Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76, 13001-13014.
6. Bonkovsky, H. L. (2002). Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 97, 1-4.
7. Chomczynski, P. & Sacchi, N. (2006). The single-step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction: twenty-something years on. Nat Protoc 1, 581-585.
8. Conesa, C., Sánchez, L., Rota, C., Pérez, M. D., Calvo, M., Farnaud, S. & Evans, R. W. (2008). Isolation of lactoferrin from milk of different species: calorimetric and antimicrobial studies. Comp Biochem Physiol B Biochem Mol Biol 150, 131-139.
9. El-Awady, M. K., Tabll, A. A., el-Abd, Y. S., Bahgat, M. M., Shoeb, H. A., Youssef, S. S., Bader el-Din, N. G., Redwan, R. M., el-Demellawy, M. (2006). HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 12, 4836-4842.
10. El-Fakharany, E. M., Tabll, A., Abd El-Wahab, A., Haroun, B. M. & Redwan, E. M. (2008). Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes. Hepat Mon 8, 101-109.
11. El-Fakharany, E. M., Haroun, B. M., Ng, T. B. & Redwan, E. R. (2010). Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells. Protein Pept Lett 17, 1031-1039.
12. El-Hatmi, H., Levieux, A. & Levieux, D. (2006). Camel (Camelus dromedarius) immunoglobulin G, a-lactalbumin, serum albumin and lactoferrin in colostrum and milk during the early post partum period. J Dairy Res 73, 288-293.
13. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Häussinger, D., Diago, M., Carosi, G. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
14. Hirashima, N., Orito, E., Ohba, K., Kondo, H., Sakamoto, T., Matsunaga, S., Kato, A., Nukaya, H., Sakakibara, K. (2004). A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol Res 29, 9-12.
15. Ikeda, M., Sugiyama, K., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. & Kato, N. (1998). Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245, 549-553.
16. Ikeda, M., Nozaki, A., Sugiyama, K., Tanaka, T., Naganuma, A., Tanaka, K., Sekihara, H., Shimotohno, K., Saito, M. & Kato, N. (2000). Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 66, 51- 63.
17. Ishibashi, Y., Takeda, K., Tsukidate, N., Miyazaki, H., Ohira, K., Dosaka-Akita, H. & Nishimura, M. (2005). Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 32, 218-223.
18. Ishii, K., Takamura, N., Shinohara, M., Wakui, N., Shin, H., Sumino, Y., Ohmoto, Y., Teraguchi, S. & Yamauchi, K. (2003). Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25, 226-233.
19. Iwasa, M., Kaito, M., Ikoma, J., Takeo, M., Imoto, I., Adachi, Y., Yamauchi, K., Koizumi, R. & Teraguchi, S. (2002). Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 97, 766-767.
20. Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C. & Manns, M. P. For the German Acute Hepatitis C Therapy Group (2001). Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345, 1452-1457.
21. Kaito, M., Iwasa, M., Fujita, N., Kobayashi, Y., Kojima, Y., Ikoma, J., Imoto, I., Adachi, Y., Hamano, H. & Yamauchi, K. (2007). Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J Gastroenterol Hepatol 22, 1894-1897.
22. Khan, J. A., Kumar, P., Paramasivam, M., Yadav, R. S., Sahani, M. S., Sharma, S., Srinivasan, A. & Singh, T. P. (2001). Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin ° at 2.6 A resolution and structural basis of its dual role. J Mol Biol 309, 751-761.
23. Konishi, M., Iwasa, M., Yamauchi, K., Sugimoto, R., Fujita, N., Kobayashi, Y., Watanabe, S., Teraguchi, S., Adachi, Y. & Kaito, M. (2006). Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 36, 27-32.
24. Legrand, D., Pierce, A., Elass, E., Carpentier, M., Mariller, C. & Mazurier, J. (2008). Lactoferrin structure and functions. Adv Exp Med Biol 606, 163-194.
25. Lönnerdal, B. (2009). Nutritional roles of lactoferrin. Curr Opin Clin Nutr Metab Care 12, 293-297.
26. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
27. Nozaki, A., Naganuma, A., Nakamura, T., Tanaka, K., Sekihara, H. & Kato, N. (2000). A reliable internally controlled RT-nested PCR method for the detection of hepatitis C virus RNA. Acta Med Okayama 54, 253-257.
28. Nozaki, A., Ikeda, M., Naganuma, A., Nakamura, T., Inudoh, M., Tanaka, K. & Kato, N. (2003). Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278, 10162-10173.
29. Ohno, O., Mizokami, M., Wu, R. R., Saleh, M. G., Ohba, K., Orito, E., Mukaide, M., Williams, R. & Lau, J. Y. (1997). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35, 201-207.
30. Redwan, R. M. & Tabll, A. (2007). Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoassay Immunochem 28, 267-277.
31. Saleh, D. A., Shebl, F., Abdel-Hamid, M., Narooz, S., Mikhail, N., El-Batanony, M., El-Kafrawy, S., El-Daly, M., Sharaf, S. (2008). Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg 102, 921- 928.
32. Sharma, S., Singh, T. P. & Bhatia, K. L. (1999). Preparation and characterization of the N and C monoferric lobes of buffalo lactoferrin produced by proteolysis using proteinase K. J Dairy Res 66, 81-90.
33. Sy, T. & Jamal, M. M. (2006). Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 3, 41-46.
34. Tanaka, K., Ikeda, M., Nozaki, A., Kato, N., Tsuda, H., Saito, S. & Sekihara, H. (1999). Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 90, 367-371.
35. Te, H. S. & Jensen, D. M. (2010). Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14, 1-21, vii.
36. Ueno, H., Sato, T., Yamamoto, S., Tanaka, K., Ohkawa, S., Takagi, H., Yokosuka, O., Furuse, J., Saito, H. (2006). Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci 97, 1105-1110.
37. Yi, M., Kaneko, S., Yu, D. Y. & Murakami, S. (1997). Hepatitis C virus envelope proteins bind lactoferrin. J Virol 71, 5997-6002.